Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1042P - Objective response rate as an intermediate surrogate endpoint to predict overall survival at 12 months

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Presenters

Won-hee Yoon

Citation

Annals of Oncology (2020) 31 (suppl_4): S645-S671. 10.1016/annonc/annonc279

Authors

W. Yoon1, P.S. Kok2, I. Marschner2, S. Lord3, M. Friedlander4, C.K. Lee5

Author affiliations

  • 1 Medical Oncology, St George Public Hospital, 2217 - Sydney/AU
  • 2 Medical Oncology Department, NHMRC Clinical Trials Centre, 1450 - Camperdown/AU
  • 3 Nhmrc Clinical Trials Centre, NHMRC Clinical Trials Centre, 2040 - Sydney/AU
  • 4 Department Of Medical Oncology, Prince of Wales Hospital, 2031 - Randwick/AU
  • 5 Medical Oncology Dept., St George Public Hospital, 2217 - Sydney/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1042P

Background

Immune checkpoint inhibitors (ICI) have a unique mechanism of action that differs from chemotherapy. Despite the poor correlation between ORR and overall survival (OS), 12-month OS (OS12) ratio is a good intermediate surrogate for OS at trial level. We aimed to develop and validate a model using ORR as a predictor for OS12 in ICI trials.

Methods

We performed an electronic search to identify eligible studies. Randomized controlled trials (RCTs) reported between January 2020-June 2019 formed the model development dataset. Correlation between ORR and OS12 were examined both at trial and ICI arm levels. Using the ICI arm data, a linear regression model was fitted using the ordinary least-squares approach, adjusting for tumour types, with ORR as a predictor for OS12. We then extracted data from an independent dataset of RCTs and single-arm ICI studies, reported from June 2019 to Jan 2020, to validate the performance of our prediction model.

Results

We identified 63 eligible trials, with 78 ICI treatment arms (58 RCTs, 20 single-arm). Thirteen trials were doublet ICI studies. The tumours types were predominantly non-small cell lung cancer (30%) and melanoma (13%). Other main tumours types included gastric/oesophageal (10%), renal cell (9%), head and neck squamous cell (8%), urothelial carcinoma (8%) and others (17%). Fifty ICI arms (from 43 RCTs) formed the model development dataset. The validation dataset comprised of 28 ICI arms (8 RCTs, 20 single arm studies). At arm level, the correlation between ORR and OS12 within ICI arms was strong, r=0.80. Complete response rate correlates poorly with OS12 (r= 0.50). The ORR-OS12 prediction model was OS12 = (1.012324 x ORR) + 0.3006825 + (0 x melanoma) + (0.0021079 x NSCLC) – (0.038521 x other tumors). When this model was applied in the validation dataset, the fitted line of scatterplot of ORR-predicted OS12 revealed close calibration with the observed OS12, r= 0.63. At trial level, the correlation between ORR risk ratio and OS HR was poor, r=0.58.

Conclusions

Our prediction model using ORR can be used to predict for OS12 in early phase ICI trials, regardless of tumour type, overcoming the issue of poor correlation between ORR and OS. This may help support decisions for phase III testing based on ORR in phase II trials of ICI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M. Friedlander: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy: MSD; Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy: Takeda; Honoraria (self), Advisory/Consultancy: Novartis; Speaker Bureau/Expert testimony: ACT Genomics; Research grant/Funding (institution): BeiGene. C.K. Lee: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Novartis Pharma SAS; Honoraria (self), Advisory/Consultancy: Pfizer Pharmaceuticals Israel; Honoraria (self): Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.